Contribution of Percutaneous Endoscopic Caecostomie in the Management of Severe Constipation Refractory to Medical Treatment

Inclusion Criteria: * Patient betwen 18 and 75 years old * Chronic constipation defined by the Rome III classification * Transit time with pellets made within 24 months preceding the inclusion visit indicating a transit time of at least 120 hours and/or with a Neurogenic bowel dysfunction ≥ 14 for patients with spina bifida and / or spinal cord injuries. * Colonoscopy made within the 5 years preceding the inclusion visit indicating the absence of colorectal organic obstacle * Anorectal manometry performed within 24 months preceding the inclusion visit performed to substantiate the information on the type of constipation * GIQLI score \<121 and Kess Questionnaire score\> 7, despite medical treatment of constipation including taking a laxative (stimulant laxative orally and / or suppository and / or retrograde enema) more than one times per week for at least two months. * Affiliation to a social security * \- Chronic constipation defined by the Rome III classification * Transit time with pellets made within 24 months preceding the inclusion visit indicating an increase of at least 120 hours compared to normal * Colonoscopy made within the 24 months preceding the inclusion visit indicating the absence of colorectal organic obstacle * Anorectal manometry performed in the 24 months preceding the inclusion visit performed to substantiate the information on the type of constipation * Score GIQLI love \<121 and Kess Questionnaire score\> 7, despite medical treatment of constipation including taking a laxative (stimulant laxative orally and / or suppository and / or retrograde enema) more than one times per week for at least two months. * Affiliation to a social security scheme * Informed consent signed Exclusion Criteria: * Severe obesity (BMI\> 40) * History of surgical resection of colon * Hypothyroidism, electrolyte disorders, insulin-dependent diabetes * Acute decompensation of depressive syndrome * Immunosuppressive therapy * Disorders of hemostasis (TP \<70%, APTT\> 1.5, thrombocytopenia \<70,000 / mm3) * Pregnant woman (positive serum beta-hCG) or breastfeeding * Adults under guardianship, curatorship or under court protection * Participation in another research protocol on the treatment of constipation